{"id":797,"date":"2024-06-12T14:41:33","date_gmt":"2024-06-12T13:41:33","guid":{"rendered":"https:\/\/project.eortc.org\/e2-radiate\/?p=797"},"modified":"2024-06-13T09:55:24","modified_gmt":"2024-06-13T08:55:24","slug":"stereotactic-body-radiotherapy-for-oligometastatic-disease","status":"publish","type":"post","link":"https:\/\/project.eortc.org\/e2-radiate\/2024\/06\/12\/stereotactic-body-radiotherapy-for-oligometastatic-disease\/","title":{"rendered":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E\u00b2-RADIatE OligoCare study"},"content":{"rendered":"

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2<\/sup>-RADIatE OligoCare study<\/h1><\/div><\/div><\/div><\/div><\/div>

Background and introduction<\/strong>
\nOptimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation.<\/p>\n

Materials and methods<\/strong>
\nAnalysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using \u03b1\/\u03b2 of 10 Gy for all primaries, and cancer-specific \u03b1\/\u03b2 of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC).<\/p>\n<\/div>

<\/div><\/div><\/div>
\"Stereotactic<\/span><\/div>
<\/div><\/div><\/div>

Results<\/strong>
\nOf the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3\u20135) and median dose per fraction was 9.7 (IQR, 7.7\u201312.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions.<\/p>\n

Conclusion<\/strong>
\nThis real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503).<\/p>\n

https:\/\/doi.org\/10.1016\/j.radonc.2024.110235<\/a><\/p>\n<\/div>

<\/div><\/div><\/div>

Sebastian M. Christ, Filippo Alongi, Umberto Ricardi, Marta Scorsetti, Lorenzo Livi, Panagiotis Balermpas, Yolande Lievens, P\u00e8tra Braam, Barbara Alicja Jereczek-Fossa, Karin Stellamans, Ivica Ratosa, Joachim Widder, Heike Peulen, Piet Dirix, Samuel Bral, Sara Ramella, Hossein Hemmatazad, Kaouthar Khanfir, Xavier Geets, Paul Jeene, Matthias Guckenberger<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":14,"featured_media":801,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/comments?post=797"}],"version-history":[{"count":5,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/797\/revisions"}],"predecessor-version":[{"id":809,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/posts\/797\/revisions\/809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media\/801"}],"wp:attachment":[{"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/media?parent=797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/categories?post=797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/project.eortc.org\/e2-radiate\/wp-json\/wp\/v2\/tags?post=797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}